Acute leukemia treated with intensive chemotherapy in patients with a history of previous chemo- and/or radiotherapy: prognostic significance of karyotype and preceding myelodysplastic syndrome. Groupe Francais de Cytogénétique Hématologique (GFCH)
- PMID: 8289504
Acute leukemia treated with intensive chemotherapy in patients with a history of previous chemo- and/or radiotherapy: prognostic significance of karyotype and preceding myelodysplastic syndrome. Groupe Francais de Cytogénétique Hématologique (GFCH)
Abstract
The prognostic significance of karyotype and of a preceding myelodysplastic syndrome (MDS) was evaluated in 57 patients with acute leukemia (AL) treated with intensive chemotherapy. All patients had a history of previous chemo- and/or radiotherapy for a neoplastic disease. Acute nonlymphocytic leukemia (ANLL) was diagnosed in 49 patients, six patients suffered from acute lymphatic leukemia (ALL) and one patient from biphenotypic and undifferentiated AL, respectively. Chromosomal aberration rate was 91%. In 54% of the patients, simple or specific chromosomal anomalies with not more than three cytogenetic defects were found, such as t(8;21), t(15;17), inv(16), t(9;11) and t(4;11). Only 37% of the patients had a karyotype highly characteristic of sAL with more than 4 structural cytogenetic defects, and/or -5, 5q-, -7, 7q-. This unusual distribution of cytogenetic defects in these patients is undoubtedly due to patient selection, since only patients who received aggressive chemotherapy were included in this study. 25 patients had previously been diagnosed as having MDS. Presence or absence of a preceding MDS and karyotype were predictive parameters for achievement of complete remission (CR). CR was obtained in 47% of the patients with normal karyotype or simple aberrations, but only in 24% of the patients with complex anomalies (p = 0.09). Patients without a prior MDS had a higher CR rate (53%) than patients with a preceding MDS (20%) (p = 0.02). CR rate was highest in patients with a normal karyotype or simple aberrations without previous MDS (56%), compared to those with complex anomalies and a prior MDS (14%) (p = 0.02). We conclude that, from a clinical point of view, AL in the former patients should be considered as de novo AL and not as secondary, therapy-related AL and that therapeutic nihilism is no longer justified in these patients.
Comment in
-
Secondary acute leukemia with 'favorable' cytogenetic abnormalities.Leukemia. 1994 Aug;8(8):1440. Leukemia. 1994. PMID: 8057686 No abstract available.
Similar articles
-
Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases.Leukemia. 1993 Sep;7(9):1315-23. Leukemia. 1993. PMID: 8371581
-
Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976-1993 and on 5098 unselected cases reported in the literature 1974-2001.Leukemia. 2002 Dec;16(12):2366-78. doi: 10.1038/sj.leu.2402713. Leukemia. 2002. PMID: 12454741
-
Correlation of cytogenetic findings with clinical features in 18 patients with inv(3)(q21q26) or t(3;3)(q21;q26).Leukemia. 1994 Aug;8(8):1318-26. Leukemia. 1994. PMID: 8057667
-
Cytogenetics in the management of acute myeloid leukemia: an update by the Groupe francophone de cytogénétique hématologique (GFCH).Ann Biol Clin (Paris). 2016 Oct 1;74(5):535-546. doi: 10.1684/abc.2016.1155. Ann Biol Clin (Paris). 2016. PMID: 27545007 Review. English.
-
Characteristics of trisomy 11 in childhood acute leukemia with review of the literature.Leukemia. 1989 Oct;3(10):695-8. Leukemia. 1989. PMID: 2674563 Review.
Cited by
-
Acute leukemia following treatment of malignant glioma.J Neurooncol. 1998 Oct;40(1):39-46. doi: 10.1023/a:1006175831785. J Neurooncol. 1998. PMID: 9874184 Review.
Publication types
MeSH terms
LinkOut - more resources
Medical
Research Materials
Miscellaneous